Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor

1 May 2025

Abstract excerpt

Background: Glypican-3 (GPC3), which is a membrane-associated antigen that is overexpressed in hepatocellular carcinoma (HCC). hGC33, a humanized anti-GPC3 antibody, has been validated as a potential antibody drug with good antitumor activity by preclinical studies and the Phase II clinical trial. However, free drug usually lack good tumor penetration. Outer membrane vesicles (OMVs) that are secreted by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to Liver physiology and pathology
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40433120
DOI: 10.2147/ijn.s513508

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat TumorPMID 40433120Read ↗

Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinomaSemantic proximity Read ↗

Structural and Functional Impact of Posttranslational Modification of Glypican-3 on Liver CarcinogenesisSemantic proximity Read ↗

Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.Semantic proximity Read ↗

Role of Glycanation and Convertase Maturation of Soluble Glypican-3 in Inhibiting Proliferation of Hepatocellular Carcinoma Cells.Semantic proximity Read ↗

Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinomaSemantic proximity Read ↗

Identification of a Glypican‐3‐Binding Peptide for In Vivo Non‐Invasive Human Hepatocellular Carcinoma DetectionSemantic proximity Read ↗

Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinomaSemantic proximity Read ↗

Chandipura viral glycoprotein (CNV-G) promotes Gectosome generation and enables delivery of intracellular therapeuticsSemantic proximity Read ↗

Glycoengineering of extracellular vesicles enhances cellular uptake and cargo delivery to target cellsSemantic proximity Read ↗

Exploring Glypican-3 Targeted CAR-NK Treatment and Potential Therapy Resistance in Hepatocellular CarcinomaSemantic proximity Read ↗

Functional targeting of Glypican-4 by a conformation-specific single-domain antibodySemantic proximity Read ↗

Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.